Methods and Findings in Experimental and Clinical Pharmacology 1998-03-01

Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.

M Shaw, S Ratanawong, P Chou, V Ray, Y Mirochnik, L Slobodskoy, M Rubenstein, P Guinan

Index: Methods Find. Exp. Clin. Pharmacol. 20(2) , 111-4, (1998)

Full Text: HTML

Abstract

Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied. Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression also significantly depressed tumor necrosis factor-alpha (TNF-alpha) expression. In the bropirimine treated group there was also a correlation between angiogenesis and cyclin D expression. Finally, linomide significantly decreased angiogenesis. Since the mechanism of action of these drugs differ, combining them at lower doses might maintain therapeutic efficacy while reducing toxicity.

Related Compounds

  • Bropirimine

Related Articles:

CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists.

2014-12-01

[J. Immunol. Methods 414 , 82-90, (2014)]

Bropirimine, an orally active anticancer agent for superficial bladder cancer.

1998-08-01

[Eur. Urol. 34(2) , 107-10, (1998)]

Current and new strategies in immunotherapy for superficial bladder cancer.

2004-09-01

[Urology 64(3) , 409-21, (2004)]

Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.

1997-05-01

[Methods Find. Exp. Clin. Pharmacol. 19(4) , 261-7, (1997)]

Complexation of the interferon inducer, bropirimine, with hydroxypropyl-beta-cyclodextrin.

2000-02-01

[Eur. J. Pharm. Sci. 9(4) , 381-6, (2000)]

More Articles...